U.S., July 2 -- ClinicalTrials.gov registry received information related to the study (NCT07679542) titled 'Dihydroartemisinin for MAFLD' on June 25.
Brief Summary: Brief Summary
Purpose:
This is a proof-of-concept clinical trial to evaluate whether Dihydroartemisinin (DHA), a medication commonly used to treat malaria, can effectively reduce liver fat in adults with Metabolic Associated Fatty Liver Disease (MAFLD). The study will also rigorously assess the safety and tolerability of DHA in this specific patient population.
Study Design:
This is a single-center, open-label, single-arm study. All qualified participants will receive the investigational treatment, with each individual serving as their own baseline control to measure pre- a...